CCR5 on the tumor surface may respond in an autocrine manner to ligands secreted by the cancer cell or in a paracrine manner to ligands secreted by the cells of the tumor microenvironment, including T cells, myeloid-derived stem cells (MDSCs), and macrophages. This evidence concerns the gene CCR5 and cancer.